A
Alcista
Alcista · 25%CRNX
$35.84
Precio del escenario
$84.950
+0.110 (+0.13%)Al cierre
Loading chart…
- Máximo
- 85.010
- Apertura
- 84.960
- Precio medio ponderado por volumen
- 84.96
- Volumen
- 8.21M
- Capitalización
- 3.43B
- Mínimo
- 84.920
- Importe
- 697.39M
- EV/EBITDA, TTM
- -9.51
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Análisis de IA of Crinetics Pharmaceuticals Inc (CRNX)
MantenerCrinetics Pharmaceuticals (CRNX) is currently trading at $84.84, very close to the analyst price target of $85. The RSI is at 82.058, indicating that the stock is overbought, which suggests caution for new buyers. The stock has shown a strong year-to-date change of +81.55% and a one-year change of +154.77%, reflecting significant growth. However, the forward P/E ratio is 0, indicating no earnings are expected in the near term, which is a risk for long-term investors. Given these factors, it's advisable to hold rather than buy at this moment, as the stock is near its acquisition price with limited upside potential.
Recomendaciones de analistas (3)
+5.24% de potencial alcista
Comprar
2 Comprar
1 Mantener
0 Vender
Actual: 84.95
Mínimo
67.00
Promedio
89.40
Máximo
105.00
UBS
Neutral
$85
2026-07-27
UBS
2026-07-27
Precio objetivo
$85
Neutral
Stifel
Mantener
$85
2026-07-08
Stifel
2026-07-08
Precio objetivo
$85
Mantener
Evercore ISI
In Line
$85
2026-07-07
Evercore ISI
2026-07-07
Precio objetivo
$85
In Line
Jefferies
Mantener
$85
2026-07-07
Jefferies
2026-07-07
Precio objetivo
$85
Mantener
JonesResearch
Mantener
$85
2026-07-07
JonesResearch
2026-07-07
Precio objetivo
$85
Mantener
Métricas de valoración
El PER previsto actual de Crinetics Pharmaceuticals Inc (CRNX) es 0.00, frente a su media de 5 años de -8.39.
Escenarios de precio de Alphio AI para CRNX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CRNX en cartera
Cronología de eventos
Noticias
8.509-01NewsfilterVertex Completes Acquisition of Crinetics Pharmaceuticals
7.008-18PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
7.508-14FoolVertex Pharmaceuticals Optimistic Future Outlook
7.508-07FoolVertex Pharmaceuticals Faces New Competitive Threats
8.508-07NASDAQ.COMVertex Pharmaceuticals Faces Competitive Pressure in CF Market
Preguntas frecuentes sobre CRNX, respondidas por Alphio AI
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Crinetics Pharmaceuticals (CRNX) is currently trading at $84.84, very close to the analyst price target of $85. The RSI is at 82.058, indicating that the stock is overbought, which suggests caution for new buyers. The stock has shown a strong year-to-date change of +81.55% and a one-year change of +154.77%, reflecting significant growth. However, the forward P/E ratio is 0, indicating no earnings are expected in the near term, which is a risk for long-term investors. Given these factors, it's advisable to hold rather than buy at this moment, as the stock is near its acquisition price with limited upside potential.
3 analysts cover CRNX: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 89.40.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.